---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: MARIPOSA"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: MARIPOSA. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 60 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence/mariposa"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: MARIPOSA

<a id="heading-3.1.4"></a>

## 3.1.4 MARIPOSA

<a id="heading-3.1.4.1"></a>

### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

#### Efficacy and safety of AD109 over 4 weeks

> “The aim of this study was to evaluate the efficacy and safety of AD109, a combination of the novel antimuscarinic agent aroxybutynin and the norepinephrine reuptake inhibitor atomoxetine, in the treatment of OSA.”
> “The purpose of the present study was to evaluate the efficacy and safety of AD109 over a longer duration (4 wk) in patients with mild to severe OSA.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.1-2"></a>

#### Company-stated objectives, including selection of the aroxybutynin dose for phase 3

> “confirm that the combination of a novel anti-muscarinic with an NRI could potentially be effective in a broad OSA population including those with mild, moderate and severe OSA;”
> “evaluate two doses of the aroxybutynin component of AD109 to determine the final dose to be advanced to Phase 3;”
> “confirm and characterize the clinical response of the aroxybutynin and atomoxetine components; and”
> “evaluate safety and tolerability of AD109 in a substantially sized patient population and extended over a 30-day period.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.4.1-3"></a>

#### Role in the design of the phase 3 trials

> “including the recent Phase 2 MARIPOSA study, a placebo-controlled dose-finding trial that informed the design of the current phase 3 trials”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="heading-3.1.4.2"></a>

### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

#### Twenty-five U.S. sites, November 2021 to August 2022

> “A phase II randomized, double-blind, placebo-controlled, parallel-arms clinical trial was performed at 25 clinical investigative sites in the United States.”
> “Enrollment began on November 29, 2021 and was completed on August 3, 2022.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.2-2"></a>

#### Registry dates

| Field | Registry entry |
| --- | --- |
| Study start (actual) | “2021-11-29” |
| Primary completion (actual) | “2022-07-20” |
| Study completion (actual) | “2022-08-03” |

Source: [ClinicalTrials.gov NCT05071612](https://clinicaltrials.gov/study/NCT05071612)

<a id="topic-3.1.4.2-3"></a>

#### Results first posted to the registry in August 2026

> “Results First Posted 2026-08-12”

Source: [ClinicalTrials.gov NCT05071612 results](https://clinicaltrials.gov/study/NCT05071612?tab=results)

<a id="topic-3.1.4.2-4"></a>

#### Start date as stated by the company

> “We initiated MARIPOSA (APC-005) in December of 2021 to evaluate the safety and efficacy of AD109 and advance dose-finding for AD109 over a one-month period of dosing.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.4.3"></a>

### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

#### Phase 2, randomized, double-blind, placebo-controlled, parallel-group, 4-week trial

> “Phase II randomized, double-blind, placebo-controlled, parallel-group, 4-week trial comparing AD109 2.5/75 mg, AD109 5/75 mg, atomoxetine 75 mg alone, and placebo (www.clinicaltrials.gov identifier NCT 05071612).”
> “Participants who met all enrollment criteria were randomized to one of four treatment arms (AD109 2.5/75 mg, AD109 5/75 mg, Ato75, or placebo) using a randomization ratio of 2:2:3:3.”
> “Participants were centrally randomized using an interactive web-based system. Participants, investigators, and study personnel were all blinded to allocation.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.3-2"></a>

#### AD504 arms in the same trial, reported separately

> “The study also evaluated another experimental drug (AD504) in early development, and those results will be reported separately.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

> “Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of AD109 and AD504 to Atomoxetine or Placebo in Obstructive Sleep Apnea”
> “Atomoxetine 75 mg tablet/Trazodone 100 mg capsule”
> “Atomoxetine 75 mg tablet/Trazodone 50 mg capsule”

Source: [ClinicalTrials.gov NCT05071612](https://clinicaltrials.gov/study/NCT05071612)

<a id="heading-3.1.4.4"></a>

### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

#### Inclusion and exclusion criteria in the publication (AHI4 of 10 to 45 by two polysomnograms)

> “Participants were adults with OSA with a mean apnea–hypopnea index using the ⩾4% desaturation criterion for hypopneas (AHI4) of 10–45 based on two screening/baseline polysomnography (PSG) studies, with <25% of events comprising central or mixed apnea.”
> “Age requirement was 18–65 years for men and 18–75 for women. Body mass index was required to be ⩽38 kg/m2 for men and ⩽40 kg/m2 for women.”
> “Key exclusion criteria were clinically important sleep disorders other than OSA, active cardiac diseases (rhythm disturbance, coronary artery disease, or heart failure), hypertension requiring more than two drugs for control, craniofacial malformation or grade ⩾3 tonsillar hypertrophy, work schedule involving night or shift work, and chronic therapy with monoamine oxidase inhibitors, norepinephrine reuptake inhibitors, α-1 antagonists, tricyclic antidepressants, strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, duloxetine), opioids, muscle relaxants, wake-promoting agents, antipsychotic agents, anticholinergic agents, or warfarin.”
> “Participants treated with CPAP, oral or nasal devices, or positional devices could enroll as long as the devices had not been used for ⩾2 weeks before the first PSG study and were not used during participation in the study.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.4-2"></a>

#### Registry inclusion criteria

> “Mean AHI 10 to 45 events/h, inclusive”
> “BMI between 18.5 and 38 kg/m2 for men and 40 kg/m2 for women, inclusive.”

Source: [ClinicalTrials.gov NCT05071612](https://clinicaltrials.gov/study/NCT05071612)

<a id="topic-3.1.4.4-3"></a>

#### Exclusion criteria as stated by the company, including insomnia

> “Main exclusion criteria were a history of insomnia or narcolepsy, craniofacial malformations, clinically significant cardiac disease (coronary artery disease, heart failure, rhythm disturbances, treatment-resistant hypertension) psychiatric or neurologic diseases, severe constipation, gastroesophageal reflux disease or urinary retention.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.4.5"></a>

### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

#### Nightly dosing with a 1-week lower-dose run-in and no dose reduction

> “The study drug was prepared as identical tablets and identical capsules to ensure adequate double-blinding. Participants received a single tablet or a tablet and a capsule.”
> “Participants were instructed to take the study drug nightly immediately before bedtime for 4 weeks.”
> “The first week of dosing was with a lower-dose run-in (AD109 2.5/37.5 mg or atomoxetine 37.5 mg), followed by the full dose taken in Weeks 2–4. Dose reduction was not permitted; dosing was discontinued if the study drug was not tolerated.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.5-2"></a>

#### Registry arm descriptions with the titration dose

> “Dose: Atomoxetine 75 mg/Aroxybutynin 2.5 mg tablet following a 1-week titration with Atomoxetine 37.5 mg/Aroxybutynin 2.5 mg tablet.”
> “Dose: Atomoxetine 75 mg/Aroxybutynin 5 mg tablet following a 1-week titration with Atomoxetine 37.5 mg/Aroxybutynin 2.5 mg tablet.”
> “Dose: Atomoxetine 75 mg tablet alone or Atomoxetine 75 mg tablet plus placebo capsule, following a 1-week titration with Atomoxetine 37.5 mg tablet alone or Atomoxetine 37.5 mg tablet plus placebo capsule. Regimens were pooled for analysis.”

Source: [ClinicalTrials.gov NCT05071612 results](https://clinicaltrials.gov/study/NCT05071612?tab=results)

<a id="topic-3.1.4.5-3"></a>

#### Dose notation in the prospectus (aroxybutynin base amounts)

> “aroxybutynin 2.3mg and atomoxetine 75mg and aroxybutynin 4.5mg and atomoxetine 75mg, respectively”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.4.6"></a>

### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

#### 3.1.4.6.1 Rationale for Using Apnea-Hypopnea Index as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

##### Primary endpoint in the publication: change in AHI4 for each AD109 dose versus placebo

> “The primary endpoint was the change from baseline to weeks 3 and 4 in AHI4 for each AD109 dose versus placebo. The secondary endpoint was the change from baseline to weeks 3 and 4 in AHI4 for Ato75 versus placebo.”
> “Although study eligibility was determined by scoring of PSG findings at the individual study sites, endpoint calculation was based on subsequent scoring by a central scoring laboratory (Sleep Strategies).”
> “Data from the two baseline PSG studies were averaged for analysis, as were data from the two treatment PSG studies (conducted after 3 and 4 weeks of dosing, respectively).”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.6.1-2"></a>

##### Endpoints of the trial

| Endpoint | Description |
| --- | --- |
| Primary | “Change from baseline in AHI4, AD109 vs placebo” |
| Secondary | “Change from baseline in AHI4, Ato75 vs placebo” |
| Tertiary, respiratory | “AHI4, HB, ODI4, AHI3a, T90” |
| Tertiary, patient-reported | “PGI-S, Short SAQLI, PROMIS scales (sleep impairment, sleep disturbance, and fatigue), ESS, QQ” |
| Tertiary, responders | “Proportion of participants with ⩾50% reduction in AHI4” |
| Safety | “Physical examination, vital signs, ECG, clinical laboratory assessment” |
| Safety, psychometric | “DSST, PVT, VOLT, CSSA” |

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.6.1-3"></a>

##### Primary endpoint in the registry: combined AD109 arms versus placebo, a difference from the publication

> “Change in Apnea-Hypopnea Index (AHI4) From Baseline: Combined AD109 Arms vs. Placebo”
> “Change in AHI4 (apnea-hypopnea index, 4% oxygen desaturation criterion; average respiratory events per hour of sleep) measured by in-lab polysomnography.”
> “Change from baseline was assessed at treatment PSG nights at approximately Day 21 (Visit 5) and Day 28 (Visit 6), modeled as repeated measures, with the reported value representing the model-based LS mean using equal (0.5/0.5) weighting between the Day 21 and Day 28 visits.”

Source: [ClinicalTrials.gov NCT05071612](https://clinicaltrials.gov/study/NCT05071612)

<a id="topic-3.1.4.6.1-4"></a>

##### Hypoxic burden as a cardiovascular risk metric

> “Hypoxic burden was calculated according to Azarbarzin and colleagues by quantifying the respiratory event–associated area under the desaturation curve for the entire night and dividing by sleep duration to yield a metric expressed in %min per hour of sleep”
> “On the contrary, AD109 has been shown to significantly decrease hypoxic burden, a metric shown to predict adverse cardiovascular outcomes”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.6.1-5"></a>

##### Epworth Sleepiness Scale change compared with the clinically important difference

> “Although the change from baseline in Epworth Sleepiness Scale score did not differ versus placebo for any drug regimen, the median change from baseline was similar to the clinically important difference of 2–3 points in CPAP-treated patients”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.6.1-6"></a>

##### AHI as the conventional primary endpoint of OSA trials, per the phase 3 design paper

> “The primary efficacy endpoint in most OSA trials is the AHI which historically has been the principal biomarker for the disease”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

<a id="heading-3.1.4.7"></a>

### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

#### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

##### Planned sample size and power

> “Approximately 200 participants were planned for enrollment, with approximately 40 in each AD109 dose group, 60 in the Ato75 group, and 60 in the placebo group.”
> “The present study had >90% power to detect a treatment difference on the primary endpoint (AHI4 for AD109 vs. placebo) at a two-sided 0.05 significance level if the true difference between the active arm and placebo arm on AHI4 was 11 units and the within-subject standard deviation was 11.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.7.1-2"></a>

##### Participants randomized and analyzed in the AD109 portion of the trial

> “Of 211 randomized patients, 181 were included in the prespecified efficacy analyses.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.7.1-3"></a>

##### Registry enrollment of 294 participants, including the AD504 arms

| Field | Registry entry |
| --- | --- |
| Enrollment (actual), all arms | “Enrollment (Actual) 294” |

Source: [ClinicalTrials.gov NCT05071612 results](https://clinicaltrials.gov/study/NCT05071612?tab=results)

<a id="topic-3.1.4.7.1-4"></a>

##### Registry primary analysis population, combined AD109 arms

> “Prespecified AD109 combined analysis group includes n=35 participants taking Atomoxetine 75mg / Aroxybutynin 5mg, and n=34 participants taking Atomoxetine 75 mg / Aroxybutynin 2.5 mg”

Source: [ClinicalTrials.gov NCT05071612 results](https://clinicaltrials.gov/study/NCT05071612?tab=results)

<a id="heading-3.1.4.7.2"></a>

#### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

##### Modified intention-to-treat, intention-to-treat, and safety populations

> “According to a predefined statistical analysis plan, there was no prespecified imputation for missing data. Thus, outcomes were analyzed based on the modified intention-to-treat (mITT) population consisting of all participants who were randomized, took at least one dose of any of the study drugs, and had at least one measurement of the primary endpoint.”
> “A post hoc analysis of the primary and secondary outcomes was performed in the ITT population (all individuals who signed the informed consent form and were randomized to any treatment arm) using the baseline observation carried forward to impute missing data. Safety assessments included all participants who received at least one dose of study drug.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.7.2-2"></a>

##### Analysis methods, sequential testing, and no adjustment for multiplicity

> “For the primary efficacy analysis, a repeated-measures model was used to assess the change in AHI4 from baseline for two doses of AD109, Ato75, and placebo. Percent reduction versus placebo was calculated using an analysis of covariance model with log-transformed data to account for the skewed distribution of values and using baseline as a covariate.”
> “Primary and secondary hypotheses were tested sequentially. Findings were considered significant if the two-sided P value was less than 0.05. Given the exploratory nature of the trial, no adjustment for multiple comparisons was performed.”
> “We present the AD109 doses separately in this article, but we have also included analysis of AHI4 for the combined AD109 doses in Table E2 in the online supplement.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.7.2-3"></a>

##### Registry analysis population and the prespecified pooling of AD109 doses

> “mITT set: all randomized participants who received ≥1 dose and had ≥1 primary endpoint measurement.”
> “The two AD109 dose arms were combined as the primary analysis group per the pre-specified SAP (v1.0, April 2022), as the study was designed and powered to evaluate the overall effect of AD109 versus placebo rather than to compare individual dose levels.”
> “This Phase 2 study was not powered to compare individual dose groups. Primary efficacy analyses evaluated prespecified pooled treatment groups, and results for individual dose arms should be interpreted descriptively.”

Source: [ClinicalTrials.gov NCT05071612 results](https://clinicaltrials.gov/study/NCT05071612?tab=results)

<a id="heading-3.1.4.8"></a>

### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

#### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

##### Screening, randomization, analysis populations, and completion

> “Of the 764 subjects screened, 211 were randomized to one of the four treatment arms (Figure 1). Of the 209 individuals who were randomized and received at least one dose of treatment (i.e., safety population), 181 had at least one measurement on the primary endpoint (i.e., mITT population) and 176 completed the study.”
> “In summary, treatment side effects resulted in one dropout in the placebo arm, 12 in the Ato75 arm, and 5 each in the AD109 2.5/75 mg and AD109 5/75 mg arms.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.1-2"></a>

##### Registry participant flow, all arms including AD504

| Milestone | AD109 75/5mg | AD109 75/2.5mg | AD504 75/100mg | AD504 75/50mg | Atomoxetine 75mg | Placebo |
| --- | --- | --- | --- | --- | --- | --- |
| Started | “41” | “42” | “43” | “40” | “64” | “64” |
| Completed | “35” | “33” | “38” | “38” | “49” | “59” |
| Not completed | “6” | “9” | “5” | “2” | “15” | “5” |
| Withdrawn due to adverse event | “5” | “5” | “3” | “1” | “12” | “1” |

Source: [ClinicalTrials.gov NCT05071612 results](https://clinicaltrials.gov/study/NCT05071612?tab=results)

<a id="heading-3.1.4.8.2"></a>

#### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

##### Demographic and clinical characteristics of the safety population

| Characteristic | Placebo (n = 63) | Atomoxetine 75 mg (n = 63) | AD109 2.5/75 mg (n = 42) | AD109 5/75 mg (n = 41) |
| --- | --- | --- | --- | --- |
| Age, years, median (IQR) | “57 (48–62)” | “56 (49–60)” | “53.5 (44–58)” | “55 (49–60)” |
| Female sex | “27 (42.9%)” | “22 (34.9%)” | “17 (40.5%)” | “19 (46.3%)” |
| BMI, kg/m2, median (IQR) | “32.0 (27.2–35.2)” | “31.2 (28.11–34.6)” | “34.5 (31.6–36.6)” | “31.2 (27.5–34.0)” |
| CPAP use | “29 (46.1%)” | “30 (47.6%)” | “18 (42.9%)” | “21 (50.2%)” |
| Black or African American | “9 (14.3%)” | “5 (7.9%)” | “11 (26.2%)” | “6 (14.6%)” |
| White | “48 (76.2%)” | “52 (82.5%)” | “28 (66.7%)” | “33 (80.5%)” |
| Hypertension | “14 (22%)” | “8 (13%)” | “6 (14%)” | “12 (29%)” |
| Diabetes | “1 (2%)” | “8 (13%)” | “3 (7%)” | “4 (10%)” |

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.2-2"></a>

##### Baseline AHI4 (4% desaturation hypopnea criterion) by arm

| Arm | Baseline AHI4, events/h, median (IQR) |
| --- | --- |
| Placebo | “20.1 (11.9–25.9)” |
| Atomoxetine 75 mg | “19.0 (11.8–28.8)” |
| AD109 2.5/75 mg | “20.5 (12.3–27.2)” |
| AD109 5/75 mg | “19.4 (13.7–26.4)” |

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.2-3"></a>

##### Inclusion of participants with AHI4 below 10 after central scoring

> “Limitations include the randomization of patients based on PSG scoring at individual sites that resulted in the inclusion of 29 patients with a baseline AHI4 <10 after central scoring.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.2-4"></a>

##### Registry baseline age and body mass index, safety set of all arms

| Characteristic | AD109 75/5mg | AD109 75/2.5mg | Atomoxetine 75mg | Placebo | Total (all six arms) |
| --- | --- | --- | --- | --- | --- |
| Participants | “41” | “42” | “63” | “63” | “292” |
| Age, years, mean (SD) | “54.2(9.24)” | “51.5(9.22)” | “52.8(10.95)” | “54.9(9.03)” | “54.2(9.49)” |
| BMI, kg/m2, mean (SD) | “31.12(4.085)” | “33.43(4.352)” | “31.16(4.716)” | “31.17(4.719)” | “31.65(4.389)” |

Source: [ClinicalTrials.gov NCT05071612 results](https://clinicaltrials.gov/study/NCT05071612?tab=results)

<a id="heading-3.1.4.8.3"></a>

#### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

##### Primary endpoint: AHI4 (4% desaturation hypopnea criterion), mITT

> “Apnea–hypopnea index with a 4% desaturation criterion (primary outcome) was reduced from a median (IQR) of 20.5 (12.3–27.2) to 10.8 (5.6–18.5) in the AD109 2.5/75 mg arm (−47.1%), from 19.4 (13.7–26.4) to 9.5 (6.1–19.3) in the AD109 5/75 mg arm (−42.9%; both P < 0.0001 vs. placebo), and from 19.0 (11.8–28.8) to 11.8 (5.5–21.5) with atomoxetine alone (−38.8%; P < 0.01 vs. placebo). Apnea–hypopnea index with a 4% desaturation criterion decreased from 20.1 (11.9–25.9) to 16.3 (11.1–28.9) in the placebo arm.”
> “Both doses of AD109 significantly decreased AHI4 compared with placebo, with mean (95% confidence interval) decreases of −7.16 (−11 to −3.3) events/h for the 2.5/75 mg dose and −7.2 (−10.97 to −3.4) for the 5/75 mg dose (P < 0.001 for both). These decreases represent a placebo-adjusted reduction in AHI4 of 47.1% (27.9–61.2) and 42.9% (22.2–58) for the two doses, respectively.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.3-2"></a>

##### Respiratory parameters from polysomnography: AHI4 (4% desaturation hypopnea criterion)

| Arm | Baseline, median (IQR) | Treatment, median (IQR) | Placebo-adjusted change, LS mean (95% CI) |
| --- | --- | --- | --- |
| Placebo | “20.1 (11.9–25.9)” | “16.3 (11.1–28.9)” | Not applicable |
| Atomoxetine 75 mg | “19.0 (11.8–28.8)” | “11.8 (5.5–21.5)” | “−5.19 (−8.6 to −1.8)” |
| AD109 2.5/75 mg | “20.5 (12.3–27.2)” | “10.8 (5.6–18.5)” | “−7.16 (−11.0 to −3.3)” |
| AD109 5/75 mg | “19.4 (13.7–26.4)” | “9.5 (6.1–19.3)” | “−7.20 (−10.97 to −3.4)” |

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.3-3"></a>

##### Respiratory parameters: AHI3a (3% desaturation or arousal hypopnea criterion)

| Arm | Baseline, median (IQR) | Treatment, median (IQR) | Placebo-adjusted change, LS mean (95% CI) |
| --- | --- | --- | --- |
| Placebo | “35.5 (25.6–41.0)” | “31.5 (23.0–41.1)” | Not applicable |
| Atomoxetine 75 mg | “33.4 (25.0–45.7)” | “26.1 (14.5–42.1)” | “−3.71 (−8.19 to 0.76)” |
| AD109 2.5/75 mg | “37.6 (30.0–47.4)” | “28.3 (18.3–39.8)” | “−7.03 (−12.08 to -1.98)” |
| AD109 5/75 mg | “35.9 (25.5–48.9)” | “22.1 (15.9–38.4)” | “−7.11 (−12.08 to -2.14)” |

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.3-4"></a>

##### Respiratory parameters: AHI4 (4% criterion) in NREM and REM sleep

| Arm | NREM baseline | NREM treatment | NREM placebo-adjusted change | REM baseline | REM treatment | REM placebo-adjusted change |
| --- | --- | --- | --- | --- | --- | --- |
| Placebo | “19.3 (9.4–27.7)” | “16.7 (9.2–27.3)” | Not applicable | “20.9 (9.3–33.9)” | “20.3 (6.1–36.1)” | Not applicable |
| Atomoxetine 75 mg | “18.4 (9.4–28.6)” | “11.4 (4.4–19.4)” | “−4.22 (−7.81 to −0.63)” | “28.1 (15.7–21.6)” | “18.5 (9.1–26.8)” | “−5.77 (−11.66 to 0.71)” |
| AD109 2.5/75 mg | “16.0 (9.6–24.7)” | “10.1 (3.5–16.4)” | “−5.38 (−9.41 to −1.34)” | “30.2 (18.1–50.7)” | “18.2 (7.6–43.5)” | “−5.67 (−12.74 to 1.41)” |
| AD109 5/75 mg | “19.0 (10.1–30.7)” | “8.3 (5.9–19.5)” | “−6.45 (−10.44 to −2.46)” | “22.6 (13.0–34.4)” | “13.8 (6.6–31.8)” | “−3.34 (−10.39 to 3.72)” |

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.3-5"></a>

##### REM sleep, sleep position, and the 3% or arousal hypopnea definition in the text

> “The effects of AD109 on AHI4 were statistically significant in non-REM (NREM) sleep and in the supine and lateral positions. AD109 also decreased the AHI when hypopneas were scored using ⩾3% desaturation or arousal criteria (P < 0.01 for both doses).”
> “Although AD109 2.5/75 mg significantly reduced AHI4 during REM sleep versus baseline (P = 0.044), the reduction was not significant when adjusted for placebo (P = 0.116), possibly because limited data were available during REM sleep during treatment.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.3-6"></a>

##### Hypoxic burden

> “Compared with placebo, hypoxic burden was reduced by −12.7 (−24.3 to −1.14) %min/h (P = 0.03) with AD109 2.5/75 mg and by −16.6 (−28 to −5.2, P = 0.005) with AD109 5/75 mg.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

| Arm | Hypoxic burden at baseline, geometric mean (95% CI), %min/h | Hypoxic burden on treatment, geometric mean (95% CI), %min/h |
| --- | --- | --- |
| Placebo | “31.1 (25.8–38.2)” | “30.1 (25.0–38.3)” |
| Atomoxetine 75 mg | “31.9 (27.2–40.5)” | “18.0 (12.4–26.0)” |
| AD109 2.5/75 mg | “31.0 (25.1–41.2)” | “19.1 (11.3–28.2)” |
| AD109 5/75 mg | “32.4 (25.6–41.5)” | “18.0 (12.0–26.1)” |

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.3-7"></a>

##### Oxygen desaturation index (4% criterion) and time below 90% saturation, placebo-adjusted

| Arm | ODI4, placebo-adjusted change, LS mean (95% CI) | T90, placebo-adjusted change, LS mean (95% CI) |
| --- | --- | --- |
| Atomoxetine 75 mg | “−4.82 (−8.16 to −1.49)” | “−5.56 (−12.67 to 1.56)” |
| AD109 2.5/75 mg | “−5.63 (−9.38 to −1.89)” | “−3.20 (−11.12 to 4.72)” |
| AD109 5/75 mg | “−6.01 (−9.71 to −2.30)” | “−3.68 (−11.50 to 4.15)” |

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.3-8"></a>

##### Responders: more than 50% reduction in AHI4 (4% criterion)

| Arm | Proportion (95% CI) with more than 50% reduction in AHI4 | Odds ratio versus placebo |
| --- | --- | --- |
| Placebo | “16.6 (8.4–28.3)” | Not applicable |
| Atomoxetine 75 mg | “39.4 (25.8–54.3)” | “3.47 (1.57–7.71)” |
| AD109 2.5/75 mg | “43.2 (26.3–61.4)” | “4.00 (1.68–9.51)” |
| AD109 5/75 mg | “44.3 (27.6–62.0)” | “4.23 (1.80–9.97)” |

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

> “Forty-four percent of participants who received AD109 had a >50% reduction in AHI4. Furthermore, AHI4 decreased to fewer than 10 events per hour in 42% of patients who received AD109.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.3-9"></a>

##### Resolution to AHI4 below 10 events per hour by baseline severity (4% criterion)

> “However, a higher proportion of participants with a baseline AHI4 in the mild to moderate range (AHI4 10–30 events/h) experienced a resolution of OSA (defined as AHI4 <10 events/h) compared with those with a baseline AHI4 in the severe range (AHI4 ⩾30; 52.2% vs. 7%; P = 0.004; Figure E2 in the online supplement).”
> “In the mITT population, a significant reduction in AHI4 occurred in patients with a baseline AHI4 as high as 45 events per hour, although fewer patients with severe OSA at baseline (AHI4 ⩾30) had an AHI4 <10 during treatment (7%) compared with those with mild (AHI4 10–15, 77%) or moderate (AHI4 15–30, 42%) OSA.”
> “Post hoc analyses showed no statistically significant differences in AHI4 reduction between subgroups based on age, sex, obesity, or baseline OSA severity (Tables E4–E7 in the online supplement).”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.3-10"></a>

##### Post hoc intention-to-treat analysis of AHI4 (4% criterion)

> “Post hoc analysis of the primary and secondary outcomes using the ITT population and considering zero change from baseline for missing data showed results similar to those in the mITT population. Compared with placebo, AHI4 decreased by −5.9 (−9.4 to −2.4) events/h (P = 0.001) with AD109 2.5/75 mg, by −6.3 (−9.8 to –2.8, P < 0.001) with AD109 5/75 mg, and by −4.3 (−7.5 to −1.2, P = 0.007) with Ato75.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.3-11"></a>

##### Registry primary outcome: change in AHI4 (4% criterion), combined AD109 arms, mITT

| Group | Participants analyzed | LS mean change from baseline (95% CI), events/hr |
| --- | --- | --- |
| AD109 combined dose arms | “69” | “-7.38 (-9.53 to -5.23)” |
| AD109 75/5mg | “35” | “-7.40 (-10.41 to -4.38)” |
| AD109 75/2.5mg | “34” | “-7.37 (-10.44 to -4.30)” |
| Placebo | “62” | “-0.21 (-2.49 to 2.07)” |

Source: [ClinicalTrials.gov NCT05071612 results](https://clinicaltrials.gov/study/NCT05071612?tab=results)

<a id="topic-3.1.4.8.3-12"></a>

##### Atomoxetine alone versus AD109: respiratory effect and sleep disruption

> “Ato75 alone reduced AHI4 by −5.19 (−8.6 to −1.8) events/h, or by 38.8% (19.5–53.6) compared with placebo (P = 0.003).”
> “Ato75 did not differ from either dose of AD109 in any respiratory parameter.”
> “AD109 did not differ significantly from atomoxetine alone (Ato75) for most respiratory parameters, suggesting that the noradrenergic activity of atomoxetine is primarily responsible for the effect of AD109 on upper airway obstruction. However, Ato75 was more likely to disturb sleep than AD109 based on objective and subjective measurements.”
> “Thus, Ato75 alone, despite improvements in sleep-disordered breathing, was not sufficiently well tolerated to be a standalone treatment for OSA.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.3-13"></a>

##### Sleep architecture: total sleep time, REM sleep, and wake after sleep onset

> “Total sleep time (TST) did not change with AD109 compared with placebo. However, Ato75 reduced TST by 21.5 (8.6–34.3) minutes compared with placebo (P = 0.001) and by 23.93 (8.89–38.98) and 16.09 (1.24–30.94) minutes compared with AD109 2.5/75 mg and 5/75 mg, respectively (P = 0.002 and P = 0.03). AD109 and Ato75 increased NREM stages 1 and 2 and reduced REM sleep compared with placebo (P < 0.001 for all).”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

| Parameter and arm | Baseline, median (IQR) | Treatment, median (IQR) | Placebo-adjusted change, LS mean (95% CI) |
| --- | --- | --- | --- |
| TST, min: placebo | “386.4 (362.3–428.0)” | “399.4 (358.5–426.5)” | Not applicable |
| TST, min: atomoxetine 75 mg | “396.4 (364.0–427.0)” | “372.2 (340.5–406.0)” | “−21.46 (−34.3 to −8.59)” |
| TST, min: AD109 2.5/75 mg | “387.5 (352.8–412.9)” | “385.5 (364.8–416.5)” | “2.48 (−12.01 to 16.96)” |
| TST, min: AD109 5/75 mg | “387.9 (360.9–425.8)” | “392.6 (355.5–421.8)” | “−5.37 (−19.65 to 8.91)” |
| REM sleep, %TST: placebo | “17.9 (14.7–20.1)” | “17.2 (13.6–20.8)” | Not applicable |
| REM sleep, %TST: atomoxetine 75 mg | “17.8 (13.7–19.0)” | “6.8 (3.5–11.3)” | “−9.32 (−11.14 to −7.50)” |
| REM sleep, %TST: AD109 2.5/75 mg | “18.6 (14.3–23.0)” | “7.5 (3.7–12.7)” | “−9.74 (−11.78 to −7.69)” |
| REM sleep, %TST: AD109 5/75 mg | “17.3 (13.5–20.1)” | “5.6 (2.5–10.2)” | “−10.79 (−12.79 to −8.78)” |
| WASO, min: placebo | “65.1 (41.5–97.8)” | “58.9 (44.5–101.8)” | Not applicable |
| WASO, min: atomoxetine 75 mg | “70.1 (44.3–98.8)” | “92.9 (61–124.3)” | “20.32 (8.07 to 32.58)” |
| WASO, min: AD109 2.5/75 mg | “75.6 (56.8–104.3)” | “78.9 (56.8–98.3)” | “0.11 (−13.69 to 13.91)” |
| WASO, min: AD109 5/75 mg | “73.3 (43.3–93.5)” | “77.0 (48.3–106.3)” | “8.21 (−5.37 to 21.79)” |

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.3-14"></a>

##### Dose selection for phase 3

> “The present study and the study of Rosenberg and colleagues suggest that the optimal dosage for AD109 may be 2.5/75 mg (21). A lower dose of atomoxetine appears to be less effective in decreasing OSA severity, and a higher dose of aroxybutynin increases antimuscarinic side effects.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="heading-3.1.4.8.4"></a>

#### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.4.8.4-1"></a>

##### PROMIS-Fatigue improvement with AD109 2.5/75 mg only

> “There was a significant improvement of Patient-Reported Outcome Measurement Information System (PROMIS) fatigue scores with AD109 2.5/75 mg compared with placebo (−3.56 [−6.77 to −0.35]; P < 0.05) and Ato75 (−3.49 [−6.84 to −0.13]; P < 0.05; Figure 4 and Table 5). There was no significant improvement in subjective outcomes with Ato75 versus placebo. However, the PROMIS sleep disturbance scale showed a trend toward increasing (i.e., worsening) with Ato75 compared with placebo (P = 0.056).”
> “It is unclear why we did not see improvement with the higher dose of AD109, although higher rates of daytime symptoms such as dry mouth, urinary hesitation, constipation, and somnolence were reported with the higher dose of aroxybutynin, suggesting more tolerability issues with the AD109 5/75 mg dose.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.4-2"></a>

##### Patient-reported outcomes, placebo-adjusted change from baseline

| Outcome | Atomoxetine 75 mg | AD109 2.5/75 mg | AD109 5/75 mg |
| --- | --- | --- | --- |
| PROMIS fatigue, adjusted T-score | “−0.07 (−2.93 to 2.79)” | “−3.56 (−6.77 to −0.35)” | “0.10 (−3.02 to 3.21)” |
| PROMIS sleep impairment, adjusted T-score | “−0.02 (−3.28 to 3.24)” | “−1.99 (−5.67 to 1.69)” | “−0.35 (−3.91 to 3.21)” |
| PROMIS sleep disturbance, adjusted T-score | “2.40 (−0.07 to 4.87)” | “1.12 (−1.66 to 3.89)” | “0.21 (−2.48 to 2.90)” |
| Modified short SAQLI | “0.54 (−4.29 to 5.37)” | “−2.28 (−7.73 to 3.17)” | “2.02 (−3.25 to 7.29)” |
| ESS score | “0.30 (−1.15 to 1.74)” | “−0.23 (−1.85 to 1.39)” | “0.64 (−0.94 to 2.22)” |
| PGI-S | “−0.25 (−0.73 to 0.23)” | “−0.16 (−0.72 to 0.41)” | “−0.19 (−0.74 to 0.36)” |
| QQ | “0.44 (−1.2 to 2.12)” | “−0.26 (−2.14 to 1.63)” | “−1.01 (−2.85 to 0.83)” |

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.4-3"></a>

##### Subset with patient-reported outcome assessments

> “Medians (IQR) were calculated from mITT set for the subset of patients with an assessment of patient-reported outcomes at baseline and on treatment (placebo, n = 57/62; ato75, n = 48/50; AD109 2.5/75, n = 32/34; AD109, 5/75 n = 35/35).”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.4-4"></a>

##### Placebo response and mild baseline symptoms as explanations offered by the authors

> “The lack of significant improvement compared with placebo on most of the patient-reported outcomes is likely related to the strong placebo effect that is common in such subjective measures (33). Indeed, most measures showed significant change from baseline in all treatment groups, including placebo. The results may also have been affected by the generally mild symptoms reported by our patient population at baseline.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="heading-3.1.4.8.5"></a>

#### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

##### Overall adverse events, discontinuations due to adverse events, and no serious adverse events

> “No serious adverse events were reported. A total of 373 adverse events were reported in 104 (49.8%) participants in the safety population: 26 (61.9%) individuals treated with AD109 2.5/75 mg, 32 (78.0%) treated with AD109 5/75 mg, 51 (81.0%) treated with Ato75, and 25 (39.7%) treated with placebo.”
> “Twenty-three (11%) individuals discontinued study participation because of adverse events: 5 (12%) in each of the AD109 groups, 12 (19%) in the atomoxetine group, and 1 (2%) in the placebo group. Events leading to study discontinuation in at least three participants were insomnia, nausea, and dry mouth.”
> “Most events were rated as mild. Two events classified as serious (nausea and migraine) led to study discontinuation in two participants in the Ato75 group.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.5-2"></a>

##### Most common adverse events (at least three participants in any group)

| Adverse event | Placebo (n = 63) | Atomoxetine 75 mg (n = 63) | AD109 2.5/75 mg (n = 42) | AD109 5/75 mg (n = 41) |
| --- | --- | --- | --- | --- |
| Any adverse event | “25 (39.7%)” | “51 (81%)” | “26 (61.9%)” | “32 (78%)” |
| Adverse event leading to discontinuation | “1 (2%)” | “12 (19%)” | “5 (12%)” | “5 (12%)” |
| Dry mouth | “3 (5%)” | “17 (27%)” | “10 (24%)” | “24 (59%)” |
| Insomnia | “2 (3%)” | “23 (37%)” | “11 (26%)” | “9 (22%)” |
| Urinary hesitation/flow decrease | “0” | “14 (22%)” | “3 (7%)” | “9 (22%)” |
| Constipation | “2 (3%)” | “2 (3%)” | “0” | “5 (12%)” |
| Nausea | “2 (3%)” | “4 (6%)” | “5 (12%)” | “4 (10%)” |
| Decreased appetite | “1 (2%)” | “5 (8%)” | “2 (5%)” | “4 (10%)” |
| Feeling jittery | “1 (2%)” | “2 (3%)” | “2 (5%)” | “3 (7%)” |
| Somnolence | “1 (2%)” | “0” | “1 (2%)” | “3 (7%)” |

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.5-3"></a>

##### Dose-dependent dry mouth and insomnia with atomoxetine alone

> “Dry mouth was a common side effect with all three drug regimens, but was much more common with AD109 5/75 mg, suggesting a dose-dependent increase with aroxybutynin”
> “Insomnia was also the most frequently reported adverse event with Ato75 and led to study discontinuation in six individuals (6.9%).”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.5-4"></a>

##### Heart rate and blood pressure versus placebo

> “Placebo-adjusted mean (95% confidence interval) change from baseline in overnight heart rate was slightly higher in all treatment groups: 7.7 (5.7–9.6), 5.1 (2.9–7.4), and 5.5 (3.3–7.1) beats/min for Ato75, Ad109 2.5/75 mg, and AD109 5/75 mg, respectively (Table 7).”
> “Diastolic blood pressure was slightly higher for the AD109 2.5/75 mg group in the evening and in the morning, at 4.7 (1.1–8.3) and 4.2 (0.5–7.9) mm Hg, respectively (Table 7).”
> “However, because there is an increased risk for cardiovascular disease in the OSA population, small increases in heart rate may potentially be more clinically important.”
> “The present trial data do not provide a definitive conclusion or understanding of the AD109 pressor effect in OSA.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

| Arm | Heart rate, overnight, beats/min | Heart rate, morning, beats/min | Systolic BP, morning, mm Hg | Diastolic BP, evening, mm Hg | Diastolic BP, morning, mm Hg |
| --- | --- | --- | --- | --- | --- |
| Atomoxetine 75 mg | “7.7 (5.7 to 9.6)” | “7.0 (3.3 to 10.6)” | “−0.8 (−5.3 to 3.8)” | “1.5 (−1.7 to 4.7)” | “1.2 (−2.1 to 4.5)” |
| AD109 2.5/75 mg | “5.1 (2.9 to 7.4)” | “5.5 (1.4 to 9.6)” | “1.9 (−3.2 to 7.0)” | “4.7 (1.1 to 8.3)” | “4.2 (0.5 to 7.9)” |
| AD109 5/75 mg | “5.5 (3.3 to 7.7)” | “7.4 (3.4 to 11.4)” | “−4.0 (−9.0 to 1.1)” | “0.5 (−3.0 to 4.0)” | “−0.8 (−4.4 to 2.8)” |

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.5-5"></a>

##### Weight and psychometric tests

> “There was no reduction in weight across all treatment arms. Results of the psychometric tests are reported in the online supplement (see Figure E1 and Table E3) and were not different compared with placebo across all treatment arms.”

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/)

<a id="topic-3.1.4.8.5-6"></a>

##### Registry adverse event table, other (not serious) events at a 5% threshold

| Adverse event | AD109 75/5mg | AD109 75/2.5mg | Atomoxetine 75mg | Placebo |
| --- | --- | --- | --- | --- |
| Total, other adverse events | “32/41 (78.05%)” | “26/42 (61.90%)” | “51/63 (80.95%)” | “25/63 (39.68%)” |
| Dry mouth | “24/41 (58.54%)” | “10/42 (23.81%)” | “20/63 (31.75%)” | “10/63 (15.87%)” |
| Middle insomnia | “4/41 (9.76%)” | “8/42 (19.05%)” | “13/63 (20.63%)” | “1/63 (1.59%)” |
| Initial insomnia | “2/41 (4.88%)” | “3/42 (7.14%)” | “7/63 (11.11%)” | “1/63 (1.59%)” |
| Urinary hesitation | “4/41 (9.76%)” | “0/42 (0.00%)” | “5/63 (7.94%)” | “0/63 (0.00%)” |
| Nausea | “4/41 (9.76%)” | “5/42 (11.90%)” | “4/63 (6.35%)” | “2/63 (3.17%)” |
| Constipation | “5/41 (12.20%)” | “0/42 (0.00%)” | “2/63 (3.17%)” | “2/63 (3.17%)” |

Source: [ClinicalTrials.gov NCT05071612 results](https://clinicaltrials.gov/study/NCT05071612?tab=results)

<a id="topic-3.1.4.8.5-7"></a>

##### Registry serious adverse events

| Measure | AD109 75/5mg | AD109 75/2.5mg | Atomoxetine 75mg | Placebo |
| --- | --- | --- | --- | --- |
| Serious adverse events | “0/41 (0.00%)” | “0/42 (0.00%)” | “0/63 (0.00%)” | “0/63 (0.00%)” |

Source: [ClinicalTrials.gov NCT05071612 results](https://clinicaltrials.gov/study/NCT05071612?tab=results)

Additional sources: [Messineo et al. (2023)](https://publications.ersnet.org/lookup/doi/10.1183/13993003.congress-2023.PA3594)

<a id="heading-3.1.4.9"></a>

### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

#### Summary

- Design: phase 2 dose-finding trial with 4 weeks of dosing; the authors describe its exploratory nature, and no adjustment for multiple comparisons was made.
- Population: AHI4 of 10 to 45 on two baseline polysomnograms, ages 18 to 65 (men) or 18 to 75 (women), and BMI up to 38 (men) or 40 (women) kg/m2. Exclusions included other clinically important sleep disorders (the prospectus names a history of insomnia), active cardiac disease, and hypertension requiring more than two drugs. PAP intolerance was not required; prior device users enrolled after 2 weeks without use, and 42.9% to 50.2% of each arm reported CPAP use.
- Eligibility scoring: eligibility used site scoring, and endpoints used central scoring, which led to inclusion of 29 participants with baseline AHI4 below 10 after central scoring.
- Primary endpoint differs by source: the publication tests each AD109 dose against placebo, and the registry names the combined AD109 arms against placebo. The registry states the trial was not powered to compare individual doses and that individual dose results should be interpreted descriptively.
- Missing data: the statistical analysis plan had no prespecified imputation, so efficacy used the modified intention-to-treat population (181 of 211 randomized); the intention-to-treat analysis was post hoc.
- Discontinuation: study discontinuation due to adverse events was 5 (12%) in each AD109 group, 12 (19%) with atomoxetine alone, and 1 (2%) with placebo.
- Outcomes: the authors attribute the lack of PRO differences to a placebo effect and mild baseline symptoms, PROs were analyzed in the subset with assessments, and the authors suggest limited REM data during treatment as a possible reason the REM reduction was not significant versus placebo.
- Reporting: registry enrollment of 294 includes two AD504 arms reported separately, and registry results were first posted on 2026-08-12, after study completion on 2022-08-03.
- Source discrepancies: the publication states no serious adverse events were reported and also that two events classified as serious led to discontinuation with atomoxetine alone, while the registry lists 0 serious adverse events in every arm. Dry mouth with placebo is 3 (5%) in the publication and 10/63 (15.87%) in the registry. The prospectus gives a start in December 2021, and the registry and publication give November 29, 2021.
- Sponsor: the prospectus describes MARIPOSA as a trial the company initiated.

Source: [Schweitzer et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10765395/); [ClinicalTrials.gov NCT05071612](https://clinicaltrials.gov/study/NCT05071612); [ClinicalTrials.gov NCT05071612 results](https://clinicaltrials.gov/study/NCT05071612?tab=results); [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
